|
|
Article: Bristol-Myers Squibb Company Announces Novel Chronic Depression Treatment Study
- Article from:
- PR Newswire
- Article date:
- January 16, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Study Evaluates the Antidepressant Serzone(R) (Nefazodone HCl)
And A Modified Form of Psychotherapy Separately and in Combination
In the Treatment of Chronic Depression
PRINCETON, N.J., Jan. 16 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today the commencement of an unprecedented chronic depression treatment study which is being conducted at 12 major institutions by some of the nation's most preeminent psychiatrists and psychologists.
The multi-center study will compare the safety and efficacy of the company's antidepressant Serzone(R) (nefazodone HCl) to a modified form of ...